Adaptive-Dose to Mediastinum With Immunotherapy (Durvalumab MEDI4736) and Radiation in Locally-Advanced Non-Small Cell Lung Cancer
Latest Information Update: 15 Jun 2023
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Etoposide; Pemetrexed
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ADMIRAL
Most Recent Events
- 14 Nov 2022 Status changed from recruiting to discontinued.
- 19 Jan 2022 Status changed from suspended to recruiting.
- 23 Dec 2021 Status changed from recruiting to suspended.